Press release
163KB
giugno 15, 2023 - Philips
IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments
Comunicato Stampa disponibile solo in lingua originale.
- The Innovative #health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by #philips, with additional resources and funding from industry partners
- The consortium will carry out research into improving clinical outcomes through less invasive treatments for lung cancer, liver cancer and soft tissue sarcomas
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in #health technology, today announced that the Philips-coordinated IMAGIO consortium of clinical partners has been awarded a EUR 24 million Innovative #health Initiative (IHI) grant, complemented with additional resources and funding from industry partners, to carry out research into less invasive cancer treatments. Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas. Leading European hospitals participating in the consortium include Leiden, Maastricht, Radboud and Utrecht University Medical Centers in the Netherlands and University Hospital of Cologne in Germany.
In Europe about 2.7 million #people are diagnosed with cancer each year. While significant advances have been made in treatment, many approaches continue to have negative side effects, impacting healthy tissues as well as targeting the cancer itself. The aim of interventional oncology is the very precise treatment of cancer cells with small instruments supported by imaging modalities such as MRI, ultrasound and CT. Treatment is carried out through targeted surgery, radiotherapy, chemotherapy, immunotherapy, or high-intensity focused ultrasound. In addition to reducing damage to healthy tissues, expanding the use of minimally or non-invasive procedures also decreases the need for major surgery.
Bert van Meurs
Chief Business Leader Image Guided Therapy and Chief Business Leader Precision Diagnosis (ad interim) at Royal Philips
"By bringing together leading university medical centers, academic partners, patient and healthcare professional organizations, as well as smaller and larger companies in the medical technology and pharmaceutical industry, the IMAGIO consortium has the potential to make a significant impact on improving cancer treatment,” said Bert van Meurs, Chief Business Leader Image Guided Therapy and Chief Business Leader Precision Diagnosis (ad interim) at Royal #philips. “We’ve chosen to focus on liver and lung cancer – two leading causes of death – alongside soft tissue sarcomas, a highly aggressive form of cancer that affects a significant proportion of young individuals, causing a lot of human suffering. By advancing established treatments and developing new approaches, we aim to improve clinical outcomes.”
Specific projects taking place in the consortium include:
- Collaboration with Radboud University Medical Center and other partners including Jansen Pharmaceutica, Pfizer, Flash Pathology, VU, ETH, ImaginAb Inc. and Eberhards Karls University Tübingen to further expand diagnosis and minimally invasive treatment of lung cancer supported by Philips' Azurion image-guided therapy platform. Read more.
- Collaboration with Leiden and Maastricht University Medical Centers to improve the diagnosis and treatment of liver cancer using CT, ultrasound, precision marking and ablation technology.
- Collaboration with University Medical Center Utrecht and TU Delft to improve the treatment of liver cancer through radioembolization (a type of radiation therapy) supported by hybrid imaging modalities. Read more.
- Collaboration between University Hospital of Cologne, Profound Medical and #philips to treat soft tissue sarcomas with MR-guided high intensity focused ultrasound (MR-HIFU) in combination with Thermosome’s lead drug candidate THE001, which is a thermosensitive liposomal formulation of doxorubicin developed in soft tissue sarcoma.
philips-image-guided-therapy-system-azurion-with-flexarm.download
2560x1707, 740KB
imagio-consortium-1-2.download
4000x2304, 2MB
News correlate |
||
|
|
|
febbraio 29, 2024
|
febbraio 20, 2024
|
novembre 27, 2023
|
|
Comunicato Stampa disponibile solo in lingua originale. New CT 5300 system provides more accurate and reliable imaging results to ... |
Comunicato Stampa disponibile solo in lingua originale. 1.88 billion lives improved by Philips’ health technology products and ser... |
Comunicato Stampa disponibile solo in lingua originale. Improved imaging and advanced tools drive standardized workflow efficiency... |
Scarica tutto 
Ti potrebbe interessare anche |
||
|
|
|
ottobre 13, 2023
|
ottobre 10, 2023
|
giugno 15, 2023
|
|
Comunicato Stampa disponibile solo in lingua originale. Animations, colors, and shapes help to improve poor situational awareness,... |
Comunicato Stampa disponibile solo in lingua originale. Two-year #partnership focused on advocacy, education, and raising awarenes... |
Comunicato Stampa disponibile solo in lingua originale. Royal #philips (NYSE: PHG, AEX: PHIA), a global leader in #health technolo... |
Inglese 
Scarica tutto 
Condividi
Condividi via mail 
Automotive
Sport
Events
Art&Culture
Design
Fashion&Beauty
Food&Hospitality
Tecnologia
Nautica
Racing
Excellence
Corporate
OffBeat
Green
Gift
Pop
Heritage
Entertainment
Health & Wellness